Drug Profile
Research programme: phosphodiesterase IV inhibitors - Dainippon Sumitomo Pharma
Alternative Names: OS-0217Latest Information Update: 08 Feb 2008
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma
- Class Pyridines
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 08 Feb 2008 Discontinued - Preclinical for Asthma in Japan (PO)
- 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
- 09 Sep 2004 Preclinical trials in Asthma in Japan (PO)